{"classes":[{"categories":[{"measurements":[{"comment":"NA - Not calculated as insufficient number of events to enable 75% percentile to be calculated","groupId":"OG000","lowerLimit":"17.9","upperLimit":"NA","value":"36.9"},{"groupId":"OG001","lowerLimit":"3.2","upperLimit":"9.0","value":"6.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"82"},{"groupId":"OG001","value":"24"}],"units":"Participants"}],"description":"Date of PFS event - date of first unconfirmed response + 1 day (and expressed in months) for unconfirmed responses only","dispersionType":"Inter-Quartile Range","groups":[{"description":"80mg once daily tablet","id":"OG000","title":"Osimertinib"},{"description":"Matching Placebo","id":"OG001","title":"Placebo"}],"paramType":"MEDIAN","populationDescription":"Full analysis set","reportingStatus":"POSTED","timeFrame":"Every 8 weeks for first 48 weeks, then every 12 weeks until radiological disease progression. Assessed up to date of DCO (05Jan24) to a maximum of approximately 63 months","title":"Duration of Response, Unconfirmed by Blinded Independent Central Review (BICR)","type":"SECONDARY","unitOfMeasure":"Months"}